LiverLearning®: Cholestatic and Autoimmune Diseases SIG: Advancing AIH Understanding and Care

This program presents an update on the current state of knowledge about autoimmune hepatitis and identify the gaps in knowledge related to the immunologic, environmental, and genetic factors underlying AIH. The program will also review clinical management, identify unmet needs, and discuss barriers along the path toward development of new therapies for AIH.Christopher L. Bowlus (Moderator) Dr. Christopher Bowlus obtained his medical degree at St. Louis University and completed his postgraduate training at University of California Davis and Yale University. Dr.

LiverLearning®: Career Development Workshop

This workshop will look at various training pathways for a career in hepatology. It will also describe various career opportunities in research, practice, education and industry, providing an overview of the rewards and challenges for each of these, and identify sources for research funding for fellows and junior faculty members.Oren K. Fix Dr. Oren Fix is the Medical Director of the Liver Transplant Program at Swedish Medical Center in Seattle, Washington, Clinical Associate Professor at the Washington State University Elson S.

LiverLearning®: Hepatitis C SIG: Navigating the road to elimination of HCV in the U.S.

This program covers the key components that support efforts to define a program toward eradication of HCV in the U.S.  The program is centered around modeling, engagement of individuals difficult to link to care and screening efforts.  Access to care and the role of advocacy is instrumental and approaches toward successful advocacy will also be discussed.John W. Ward John W. Ward, MD created and directs the Coalition for Global Hepatitis Elimination of the Task Force for Global Health.

LiverLearning®: Clinical Research Workshop: Researching and Applying Precision Medicine in Hepatology

Precision medicine has the potential to completely revolutionize health care research and treatment – allowing doctors and researchers to more accurately predict which treatment and prevention strategies for a particular disease will work in individual patients or groups of patients vs. a one-size-fits all paradigm.

LiverLearning®: Hepatotoxicity SIG: Herbal and Dietary Supplement Induced Liver Injury: Defining the Future

This program will focus on liver injury due to herbal and dietary supplements. The program will begin with a description of a realworld case of liver injury due to OxyElite Pro, which highlights the challenges faced by diagnosticians and researchers in establishing causation for hepatotoxicity due to herbal and dietary supplements. The program will also review the role of the FDA, CDC and chemists, including scientists with the National Center for Natural Products Research, at the University of Mississippi, who perform product chemical analyses.Victor J. Navarro Victor J.

The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis

Eva Santamaría, Carlos M. Rodríguez‐Ortigosa, Iker Uriarte, Maria U. Latasa, Raquel Urtasun, Gloria Alvarez‐Sola, Marina Bárcena‐Varela, Leticia Colyn, Sara Arcelus, Maddalen Jiménez, Kathleen Deutschmann, Ana Peleteiro‐Vigil, Julian Gómez‐Cambronero, Malgorzata Milkiewicz, Piotr Milkiewicz, Bruno Sangro, Verena Keitel, Maria J. Monte, Jose J.G. Marin, Maite G. Fernández‐Barrena, Matias A. Ávila, Carmen Berasain – 8 November 2018 – Intrahepatic accumulation of bile acids (BAs) causes hepatocellular injury.

Subscribe to